By Daniella Parra March Biosciences was granted an orphan drug designation from the FDA to MB-105, its CD5-targeted CAR-T ...

Company prepares to advance to Phase 2 clinical trial in early 2025HOUSTON, Jan. 28, 2025 (GLOBE NEWSWIRE) -- March Biosciences (March Bio), an ...

Biosciences receives US FDA orphan drug designation for MB-105 to treat relapsed/refractory CD5-positive T-cell lymphoma: Houston Thursday, January 30, 2025, 17:00 Hrs [IST] ...

MB-105, a first-in-class CD5-targeted CAR T-cell therapy, received FDA orphan drug designation for relapsed/refractory T-cell ...

Fintel reports that on January 23, 2025, Piper Sandler initiated coverage of Bright Minds Biosciences (NasdaqCM:DRUG) with a ...

NEW YORK CITY, NY / ACCESS Newswire / January 29, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm ...

Company management will host a conference call and webcast beginning at 4:30 p.m. ET/ 1:30 p.m. PT that SAN DIEGO, March 07, 2024 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX ...

Discover the top-performing biotech stocks in 2024! From oncology to psychedelics some companies showed remarkable results.

today released its financial and operating results for the three months ended March 31, 2024, reporting significantly reduced costs and further progress in its commercial expansion. Willow Biosciences ...

Healthcare’s resilience makes it a go-to sector during market volatility. With steady demand, innovation, and aging demographics driving growth, investors could consider investing in fundamentally ...

Maruzi ranch, which used to be a den of criminals Apac District is gradually becoming a production hub. In 2015, seven people ...